Utility of Soluble Angiogenic Factors As Biomarker for Disease Severity and Prognosis.

Ruyuan Zhang,Hongping Qu,Min Dong,Ya-Bin Tang

DOI: https://doi.org/10.1097/mcg.0b013e318236effa

2012-01-01

Journal of Clinical Gastroenterology

Abstract:To the Editor: It is with great interest that we read the article by Espinosa et al published in issue 7 of Journal of Clinical Gastroenterology, 2011. In their study, they measured the serum levels of angiogenic factors in patients with acute pancreatitis and found that plateletderived growth factor (PDGF-BB) and hepatocyte growth factor (HGF) were significantly higher in patients with severe acute pancreatitis and in patients with unfavorable clinical evolution, well correlated with severity of acute pancreatitis. Their results suggest that soluble angiogenic factors such as serum levels of PDGF-BB and HGF may be useful as biomarkers for predicting a poor prognosis of acute pancreatitis. This is the first report concerning serum levels of PDGF-BB and HGF in acute pancreatitis patients. The study has favorable outcomes, but more attention should be given to some important issues. Levels of soluble angiogenic factors such as circulating vascular endothelial growth factor (VEGF) have widely been used as biomarkers for disease severity and prognosis in various diseases. Previous studies showed that in addition to their function in hemostasis, platelets store, and release angiogenic growth factors such as PDGF-BB, HGF, VEGF, angiopoietin-1 (ang-1) and others. Although platelets are important sources of angiogenic factors, less attention is paid to its impact on the level of soluble angiogenic factors determined in vitro and aiming more at measuring the circulating angiogenic factors in vivo. In Espinosa et al’s study, serum levels of PDGF-BB and HGF were used. However, serum may contain high levels of PDGF-BB and HGF because of its release by activated platelets during clotting. Therefore, these angiogenic factors levels in serum, which correlate closely with blood platelets count and activation, may not reflect the actual circulating concentration of soluble angiogenic factors in vivo. For example, falsely high ang-1 serum levels have been observed because of ex vivo activation of platelets upon clotting in serum tubes. David et al had earlier published similar falsely high ang-1 levels in patients’ sera, unaware of the ex vivo release from platelets. The same is probably true for VEGF. Most recently, even in citrate or ethylene diamine tetra-acetic acid plasma, where less platelet activation and subsequent VEGF release is expected than in serum, Niers et al found that in contrast with publications before, the “true” freely circulating VEGF levels were not elevated in the majority of cancer patients when determining the plasma levels of VEGF with or without inhibition of platelet activation. It appears that previously reported elevated plasma VEGF levels widely used as biomarkers in cancer were because of artificial release from ex vivo activated platelets during the blood harvest procedure. Because Espinosa et al measured the levels of all angiogenic factors in patients’ serum, some doubts may arise about the validity and biological relevance behind these findings. There is a possibility that their results may be confounded by the release of angiogenic factors from ex vivo platelet activation. Unfortunately, except for VEGF and ang-1, the preanalytic performances of other angiogenic factors assays such as PDGF-BB and HGF have not so far been reported. For this reason, before correction for artificial PDGF-BB and HGF release by platelets activated ex vivo, the results of such soluble angiogenic factors from nonstandardized measurements in plasma and serum should be interpreted with caution. We suggest that, to assess the usefulness of the levels of soluble angiogenic factors such as serum PDGF-BB and HGF as biomarkers for predicting the outcomes of patients with acute pancreatitis and other diseases and also to rule out variable ex vivo platelet activation in the samples, studies need to include additional data such as platelet counts to clarify if the levels of soluble angiogenic factors are confounded by sample preparation. Another alternative is to determine the circulating levels of these angiogenic factors with inhibition of platelet activation in vitro.